Larimar Therapeutics, Inc. (LRMR) DCF Valuation

Larimar Therapeutics, Inc. (LRMR) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Larimar Therapeutics, Inc. (LRMR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (LRMR) DCF Calculator enables you to evaluate Larimar Therapeutics, Inc. valuation using real-world financial data while offering complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -23.1 -42.6 -50.1 -35.1 -41.4 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .1 .2 .3 .3 .3 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -23.2 -42.8 -50.5 -35.4 -41.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 1.0 92.6 70.1 118.4 86.8 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .2 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories 3.2 .0 -.2 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 3.5 2.6 1.7 1.7 1.3 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.1 -.1 -.3 -.1 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -23.2 -42.6 -50.1 -34.2 -41.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.8 -40.3 -51.1 -34.0 -42.0 -1.3 .0 .0 .0 .0
WACC, % 7.71 7.71 7.71 7.71 7.71 7.71 7.71 7.71 7.71 7.71
PV UFCF
SUM PV UFCF -1.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -21
Equity Value 20
Diluted Shares Outstanding, MM 44
Equity Value Per Share 0.46

What You Will Get

  • Comprehensive LRMR Financials: Access to both historical and projected data for precise valuation.
  • Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Dynamic computation of intrinsic value and NPV.
  • Scenario Modeling: Evaluate various scenarios to assess Larimar Therapeutics' future performance.
  • User-Friendly Design: Crafted for professionals while remaining approachable for newcomers.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Larimar Therapeutics, Inc. (LRMR).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates to fit your analysis.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Larimar Therapeutics, Inc. (LRMR).
  • Interactive Dashboard and Charts: Visual representations of key valuation metrics for straightforward analysis and decision-making.

How It Works

  • Download: Access the ready-to-use Excel file with Larimar Therapeutics, Inc.'s (LRMR) financial data.
  • Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations update in real-time.
  • Test Scenarios: Create multiple projections and compare outcomes instantly.
  • Make Decisions: Use the valuation results to guide your investment strategy.

Why Choose Larimar Therapeutics, Inc. (LRMR)?

  • Innovative Solutions: Pioneering therapies for rare diseases that address unmet medical needs.
  • Expertise in Development: A dedicated team with extensive experience in biotech and pharmaceuticals.
  • Commitment to Quality: Adhering to rigorous standards ensures the safety and efficacy of our treatments.
  • Patient-Centric Approach: Focused on improving the lives of patients through targeted therapies.
  • Proven Track Record: Backed by successful clinical trials and partnerships with leading organizations.

Who Should Use This Product?

  • Investors: Accurately assess Larimar Therapeutics’ fair value before making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Larimar Therapeutics (LRMR).
  • Consultants: Efficiently modify the template for valuation reports tailored to clients interested in Larimar Therapeutics (LRMR).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Larimar Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Larimar Therapeutics, Inc. (LRMR).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.